Drug-induced phospholipidosis is caused by blockade of mannose 6-phosphate receptor-mediated targeting of lysosomal enzymes

Biochemical and Biophysical Research Communications

Volumn 377, Issue 1, 2008, Pages 268-274

  Ikeda, Kazuhiko ^a,b   Hirayama, Masahiro ^a   Hirota, Yuko ^a   Asa, Erika ^a   Seki, Jiro ^b   Tanaka, Yoshitaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Cationic amphiphilic drug; Drug induced phospholipidosis; Endosomes; Lysosomal enzymes; Mannose 6 phosphate IGF II receptor

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; AMOXICILLIN; BETA N ACETYLHEXOSAMINIDASE; CAPTOPRIL; CATHEPSIN D; CHLOROQUINE; CHLORPROMAZINE; EARLY ENDOSOME ANTIGEN 1; ERYTHROMYCIN; GENTAMICIN; HALOPERIDOL; IMIPRAMINE; LYSOSOME ENZYME; MAPROTILINE; PERHEXILINE; QUINIDINE; SOMATOMEDIN B RECEPTOR; TAMOXIFEN; THIORIDAZINE; TILORONE; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ARTICLE; CELL STRAIN COS1; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOSOME; ENZYME RELEASE; IMMUNOFLUORESCENCE MICROSCOPY; KIDNEY CELL; LIPIDOSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN FIBROBLAST; WESTERN BLOTTING;

AMIODARONE; ANIMALS; BETA-N-ACETYLHEXOSAMINIDASES; CELLS, CULTURED; ENDOSOMES; KIDNEY; LIPIDOSES; LYSOSOMES; PHOSPHOLIPIDS; RATS; RECEPTOR, IGF TYPE 2; SURFACE-ACTIVE AGENTS;

RATTUS;

EID: 54449089714     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.09.121     Document Type: Article

References (28)

1. Kodavanti U.P., and Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 42 (1990) 327-354
2. Reasor M., and Kacew S. Drug-induced phospholipidosis: are there functional consequence?. Exp. Biol. Med. (Maywood) 226 (2001) 825-830
3. Anderson N., and Borlak J. Drug-induced phospholipidosis. FEBS Lett. 580 (2006) 5533-5540
4. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 25 (1997) 53-60
5. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu. Rev. Biochem. 61 (1992) 307-330
6. Hirosako K., Imasato H., Hirota Y., Kuronita T., Masuyama N., Nishioka M., Umeda A., Fujita H., Himeno M., and Tanaka Y. 3-Methyladenine specifically inhibits retrograde transport of cation-independent mannose 6-phosphate/insulin-like growth factor II receptor from the early endosome to the TGN. Biochem. Biophys. Res. Commun. 316 (2004) 845-852
7. Kuronita T., Eskelinen E.L., Fujita H., Saftig P., Himeno M., and Tanaka Y. A role for the lysosomal membrane protein LGP85 in the biogenesis and maintenance of endosomal and lysosomal morphology. J. Cell Sci. 115 (2002) 4117-4131
8. Tanaka Y., Guhde G., Suter A., Eskelinen E.L., Hartmann D., Lüllmann-Rauch R., Janssen P.M., Blanz J., von Figura K., and Saftig P. Accumulation of autophagic vacuoles and cardiomyopathy in LAMP-2-deficient mice. Nature 406 (2000) 902-906
9. Niwa K., Tanaka R., Murase H., Ishikawa T., Fujita H., Himeno M., and Tanaka Y. Two lysosomal membrane proteins, LGP85 and LGP107, are delivered to late endosomes/lysosomes through different intracellular routes after exiting from the trans-Golgi network. Biochem. Biophys. Res. Commun. 301 (2003) 833-840
10. Hirota Y., Masuyama N., Kuronita T., Fujita H., Himeno M., and Tanaka Y. Analysis of post-lysosomal compartments. Biochem. Biophys. Res. Commun. 314 (2004) 306-312
11. Hirota Y., Kuronita T., Fujita H., and Tanaka Y. A role of Rab5 activity for biogenesis and maintenance of endosomal/lysosomal compartments. Biochem. Biophys. Res. Commun. 364 (2007) 40-47
12. Tanaka Y., Tanaka R., Kawabata T., Noguchi Y., and Himeno Y.M. Lysosomal cysteine protease, cathepsin B, is targeted to lysosomes by the mannose 6-phosphate-independent pathway in rat hepatocytes: site-specific phosphorylation in oligosaccharides of the proregion. J. Biochem. 128 (2000) 39-48
13. Umeda A., Fujita H., Kuronita T., Hirosako K., Himeno M., and Tanaka M.Y. Distribution and trafficking of MPR300 is normal in cells with cholesterol accumulated in late endocytic compartments: evidence for early endosome-to-TGN trafficking of MPR300. J. Lipid Res. 44 (2003) 1821-1832
14. Yasuda Y., Kageyama T., Akamine A., Shibata M., Kominami E., Uchiyama Y., and Yamamoto K. Characterization of new fluorogenic substrates for the rapid and sensitive assay of cathepsin E and cathepsin D. J. Biochem. (Tokyo) 125 (1999) 1137-1143
15. 2 -terminal transmembrane and lumenal domains of LGP85 are needed for the formation of enlarged endosomes/lysosomes. Traffic 6 (2005) 895-906
16. Atienzar F., Gerets H., Dufrane S., Tilmant K., Cornet M., Dhalluin S., Ruty B., Rose G., and Canning M. Determination of phospholipidosis potential based on gene expression analysis in HepG2 cells. Toxicol. Sci. 96 (2007) 101-114
17. Mingeot-Leclercq M.P., Laurent G., and Tulkens P.M. Biochemical mechanism of aminoglycoside-induced inhibition of phosphatidylcholine hydrolysis by lysosomal phospholipases. Biochem. Pharmacol. 37 (1988) 591-599
18. Jansen S.M., Groener J.E.M., and Poorthuis B.J.H.M. Lysosomal phospholipase activity is decreased in mucopilidosis II and III fibroblasts. Biochim. Biophys. Acta 1436 (1999) 363-369
19. Reitman M.L., Varki A., and Kornfeld S. Fibroblasts from patients with I-cell disease and pseudo-Hurler polydystrophy are deficient in uridine 5′-diphosphate N-acetylglucosamine: glycoprotein N-acetylglucosaminylphosphotransferase activity. J. Clin. Invest. 67 (1981) 1574-1579
20. Baritussio A., Marzini S., Agostini M., Alberti A., Cimenti C., Bruttomesso D., Manzato E., Quaglino D., and Pettenazzo A. Amiodarone inhibits lung degradation of SP-A and perturbs the distribution of lysosomal enzymes. Am. J. Physiol. Lung Cell Mol. Physiol. 281 (2001) L1189-L1199
21. Meyer C., Zizioli D., Lausmann S., Eskelinen E.L., Hamann J., Saftig P., von Figura K., and Schu P. mu1A-Adaptin-deficient mice: lethality, loss of AP-1 binding and rerouting of mannose 6-phosphate receptors. EMBO J. 19 (2000) 2193-2203
22. Sawada H., Takami K., and Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 83 (2005) 282-292
23. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Masotto I., Mutinelli C., Valko K., and Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. 19 (2003) 161-176
24. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., and Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 90 (2006) 133-141
25. Fujimura H., Dekura E., Kurabe M., Shimazu N., Koitabashi M., and Toriumi W. Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development. Exp. Toxicol. Pathol. 58 (2007) 375-382
26. Bhandari N., Figueroa D.J., Lawrence J.W., and Gerhold D.L. Phospholipidosis assay in HepG2 cells and rat or rhesus hepatocytes using phospholipid probe NBD-PE. Assay Drug Dev. Technol. 6 (2008) 407-419
27. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., and Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies. Toxicol. Sci. 99 (2007) 162-173
28. Hirode M., Ono A., Miyagishima T., Nagao T., Ohno Y., and Urushidani T. Gene expression profiling in rat liver treated with compounds inducing phospholipidosis. Toxicol. Appl. Pharmacol. 229 (2008) 290-299